Ceregate builds a hardware‑agnostic computer‑brain interface platform that restores and reimagines human senses by creating a direct communication channel with the brain. The platform supports a variety of therapeutic applications, enabling clinicians to deliver targeted neural stimulation or feedback without being tied to specific devices. By abstracting the underlying hardware, Ceregate allows developers to focus on creating new sensory‑restoration treatments and research tools.
Funding
Funding not disclosed
3ORMFounders
Product
Problem
Patients with neurological and sensory disorders such as Parkinson’s disease, vestibular dysfunction, and mobility impairments often rely on invasive neuromodulation implants that are limited to stimulation only, leaving a gap for bidirectional communication with the nervous system. This restricts therapeutic options and hampers the development of advanced neural interventions that could restore or enhance sensory functions.
Solution
Ceregate provides a hardware‑agnostic computer‑brain interface (CBI) platform that repurposes existing neuromodulation implants—such as deep brain stimulation (DBS) and spinal cord stimulation (SCS) devices—to transmit information directly to neural circuits. By adding software‑driven encoding and decoding capabilities, the platform enables bidirectional communication, allowing clinicians to deliver targeted neural cues (e.g., rhythmic signals, Morse code, postural information) without requiring new hardware. The solution is designed to integrate with current clinical workflows and healthcare infrastructure, facilitating rapid adoption and expanding treatment options for a range of sensory and motor disorders. Clinical validation across more than 85 patient trials demonstrates reliability across multiple neural pathways, and ongoing FDA trials aim to secure Breakthrough Device status.
Target Audience
Primary customers are neurologists, movement‑disorder specialists, and rehabilitation clinicians seeking advanced neural therapies for Parkinson’s disease, vestibular disorders, and other sensory‑motor conditions.
Features
- Software layer that converts existing DBS and SCS implants into bidirectional computer‑brain interfaces
- Ability to transmit rhythmic cues, Morse code, and postural information for therapeutic applications
- Hardware‑agnostic design compatible with a variety of implanted neuromodulation devices
- Clinically validated in over 85 patient trials, showing efficacy in improving mobility and balance
- Scalable platform that integrates with existing medical device ecosystems and healthcare IT systems
- Pursuing FDA Breakthrough Device designation to accelerate regulatory approval